3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
9
Thoracic
3
Gastrointestinal
3
Other solid neoplasm
2
Gynecologic
2
Sarcoma
1
NET
1
Genitourinary
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Renal Cell
132
Carcinoma, Transitional Cell
91
Carcinoma, Non-Small-Cell Lung
84
Urinary Bladder Neoplasms
81
Melanoma
75
Squamous Cell Carcinoma of Head and Neck
50
Prostatic Neoplasms
49
Colorectal Neoplasms
41
Ovarian Neoplasms
36
Stomach Neoplasms
35
Triple Negative Breast Neoplasms
33
Neoplasm Metastasis
32
Uterine Cervical Neoplasms
31
Neoplasms
28
Kidney Neoplasms
27
Breast Neoplasms
27
Parkinson Disease 4, Autosomal Dominant Lewy Body
26
Lung Neoplasms
26
Pancreatic Neoplasms
23
Carcinoma, Hepatocellular
23
Esophageal Neoplasms
21
Head and Neck Neoplasms
20
Endometrial Neoplasms
18
Small Cell Lung Carcinoma
16
Carcinoma, Merkel Cell
11
Mesothelioma
9
Cholangiocarcinoma
9
Ureteral Neoplasms
8
Sarcoma
8
Carcinoma, Ovarian Epithelial
8
Interventions
Docetaxel
7
Trastuzumab
3
sargramostim
2
entrectinib
2
Radiotherapy
2
Polymerase Chain Reaction
2
Immunohistochemistry
2
Gene Expression Profiling
2
Fluorodeoxyglucose F18
2
Flow Cytometry
2
Erlotinib Hydrochloride
2
Biopsy
2
zanidatamab
1
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trastuzumab deruxtecan
1
tipifarnib
1
tanespimycin
1
pertuzumab
1
pembrolizumab
1
oncogene protein E7, Human papillomavirus type 16
1
entinostat
1
alectinib
1
aldesleukin
1
X-Ray Therapy
1
Vorinostat
1
Thalidomide
1
Taxes
1
Ritonavir
1
Quality of Life
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
pembrolizumab
×
Genitourinary
×
Clear all
NCT04140526
2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2
Active not recruiting
733 enrolled